The Chronic Malignancies Working Party (CMWP) is looking for transplant centers who treated patients with Hairy Cell Leukemia (HCL) with an allogeneic hematopoietic stem cell transplantation (HSCT) between 1985 and 2018.
We know that HCL can be successfully treated for many years by chemotherapy or immunochemotherapy and that promising drugs are emerging, including BRAF inhibitors and moxetumomab pasudotox. However, selected eligible patients with refractory disease can be candidate for cellular therapy including allogeneic HSCT.
The aim of this retrospective study is to describe the clinical outcomes of allogeneic HSCT in such patients with HCL and explore the difference in survival outcome by HCL subtype (classic vs variant), clinical patient characteristics and prior treatment lines.
A data request for this retrospective study was sent out at January 7th this year. If you have eligible patients for this study and did not receive the study invitation, please contact us at email@example.com. Your participation will be highly appreciated.